Affibody-mediated PET imaging of HER3 expression in malignant tumours

Maria Rosestedt, Ken G. Andersson, Bogdan Mitran, Vladimir Tolmachev, John Lofblom, Anna Orlova, Stefan Ståhl

Research output: Contribution to journalArticlepeer-review

42 Citations (Scopus)

Abstract

Human epidermal growth factor receptor 3(HER3) is involved in the progression of various cancers and in resistance to therapies targeting the HER family. In vivo imaging of HER3 expression would enable patient stratification for anti-HER3 immunotherapy. Key challenges with HER3-targeting are the relatively low expression in HER3-positive tumours and HER3 expression in normal tissues. The use of positron-emission tomography (PET) provides advantages of high resolution, sensitivity and quantification accuracy compared to SPECT. Affibody molecules, imaging probes based on a non-immunoglobulin scaffold, provide high imaging contrast shortly after injection. The aim of this study was to evaluate feasibility of PET imaging of HER3 expression using 68Ga-labeled affibody molecules. The anti-HER3 affibody molecule HEHEHE-Z08698-NOTA was successfully labelled with 68Ga with high yield, purity and stability. The agent bound specifically to HER3-expressing cancer cells in vitro and in vivo. At 3 h pi, uptake of 68Ga-HEHEHE-Z08698-NOTA was significantly higher in xenografts with high HER3 expression (BT474, BxPC-3) than in xenografts with low HER3 expression (A431). In xenografts with high expression, tumour-to-blood ratios were >20, tumour-to-muscle >15, and tumour-to-bone >7. HER3-positive xenografts were visualised using microPET 3 h pi. In conclusion, PET imaging of HER3 expression is feasible using 68Ga-HEHEHE-Z08698-NOTA shortly after administration.

Original languageEnglish
Article number15226
JournalScientific Reports
Volume5
DOIs
Publication statusPublished - 19 Oct 2015
Externally publishedYes

ASJC Scopus subject areas

  • General

Fingerprint Dive into the research topics of 'Affibody-mediated PET imaging of HER<sub>3</sub> expression in malignant tumours'. Together they form a unique fingerprint.

Cite this